Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q3 2017 Earnings Presentation

28 slides from Sucampo Pharmaceuticals's earnings presentation, Nov 1, 2017

  1. Slide 1: Third Quarter 2017 Corporate Update and Financial Results

    November 1, 2017 Third Quarter 2017 Corporate Update and Financial Results 1

  2. Slide 2: Introductions and Forward-Looking Statements

    Introductions and Forward - Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs 2

  3. Slide 3: Agenda

    Agenda Introductions and Forward - Looking Statements Silvia Taylor Corporate Update Peter Greenleaf Pipeline Update Peter Kiener, D. Phil Financial Update Peter Pfreundschuh Closing Remarks Peter Greenleaf 3

  4. Slide 4: Forward Looking Statement

    Forward Looking Statement This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to dif fer

  5. Slide 5: Non-GAAP Metrics

    Non - GAAP Metrics This presentation contains four financial metrics (Adjusted Net Income, EBITDA, Adjusted EBITDA and Free Cash Flow) that are con sidered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metr ics sh

  6. Slide 6: Q3 2017

    Q3 2017 Corporate Update Peter Greenleaf, Chairman and CEO 6

  7. Slide 7: Significant Corporate Progress

    Significant Corporate Progress • Advanced key pipeline programs • VTS - 270 – Pivotal data read - out in Niemann - Pick Disease in 2018 • CPP - 1X/sulindac fixed dose combination • FDA accepted filing for AMITIZA in pediatric functional constipation in children 6 - 17 years of age, with Priority Rev

  8. Slide 8: Guidance Increased for 2017

    Guidance Increased for 2017 • Revised guidance includes milestone of $10 million from Mylan expected in fourth quarter 8 Current Previous Total Revenue $250 to $255 million $220 to $230 million Adjusted Net Income $63 to $68 million $56 to $66 million Adjusted EBITDA $120 to $125 million $109 to $11

  9. Slide 9: VTS-270 Program Update

    VTS - 270 Program Update • VTS - 270 for the treatment of Niemann - Pick Disease (NPC - 1) in global pivotal registration program • Ultra - rare disorder with devastating and ultimately fatal outcome • Orphan drug designation in both U.S. and Europe and breakthrough therapy designation in U.S. • Pha

  10. Slide 10: CPP-1X/sulindac Phase 3 Program Update

    CPP - 1X/sulindac Phase 3 Program Update • In Phase 3 program for the treatment of Familial Adenomatous Polyposis (FAP) • Rare disease that leads to cancer of GI tract in 100% of patients • Partnership with Cancer Prevention Pharmaceuticals • Fast - Track status granted by FDA • If relevant criteria

  11. Slide 11: Strong Q3 2017 U.S. AMITIZA Performance

    Strong Q3 2017 U.S. AMITIZA Performance • Takeda’s AMITIZA net sales for royalty calculation purposes • Q3 grew 6% YoY to $115.2M • Driven by increased volume and price • Royalty revenue grew 11% YoY to $23.0M • U.S. AMITIZA product sales to Takeda of $13.1M • Total U.S. revenue of $36.2M • AMITIZA

  12. Slide 12: Strong Japan AMITIZA Performance

    Strong Japan AMITIZA Performance • Sucampo Q3 revenue: $20.5M, growth of 18% YoY • Growth driven by volume • Increased 35% YoY • Patient demand for AMITIZA remains strong in an increasingly competitive market • Expect AMITIZA to continue to hold solid position with prescribers and benefit from incre

  13. Slide 13: Pipeline Update

    Pipeline Update Peter Kiener, D. Phil, CSO 13 13

  14. Slide 14: VTS-270 for Treatment of NPC-1

    VTS - 270 for Treatment of NPC - 1 14 Until regulatory decision • IT injections every 2 weeks • Trial fully enrolled • All patients currently in parts B or C • Part B is key phase for NDA submission; completes end of March 2018 • Pivotal data expected in mid - 2018 • Potential regulatory approval in

  15. Slide 15: CPP-1X/sulindac for Treatment of FAP

    CPP - 1X/sulindac for Treatment of FAP • CPP - 1X/sulindac is being developed to treat Familial Adenomatous Polyposis (FAP), a predominately genetic disease • If left untreated, FAP eventually develops into colon cancer in 100% of patients • Orphan disease in U.S. and Europe • Ongoing Phase 3 study

  16. Slide 16: AMITIZA for Treatment of Pediatric Functional Constipation

    AMITIZA for Treatment of Pediatric Functional Constipation • FDA accepted sNDA filing for life cycle management program for AMITIZA in children age 6 - 17 with pediatric functional constipation • Priority Review designation • PDUFA date Jan 28, 2018 • Ongoing commitment to pediatric functional const

  17. Slide 17: Product Pipeline

    Product Pipeline 17 Sucampo Program Option Program Target First Indication Development Stage (s)NDA/MAA Filing Approval AMITIZA CIC2 Pediatric functional constipation (6 - 17 yrs.) P3 2017 2018 CPP - 1X/sulindac combination product Polyamines Familial Adeneomatous Polyposis P3 2018/19 2019 VTS - 270

  18. Slide 18: Financial Update

    Financial Update Peter Pfreundschuh, CFO 18 18

  19. Slide 19: Financial and Operational Performance Summary of Results

    Financial and Operational Performance Summary of Results Q3 - 17 Q3 - 16 Net Income GAAP $10.4M $8.1M EPS GAAP – diluted $0.19 $0.19 EBITDA $27.4M $35.6M Adjusted Net Income $15.8M $12.9M Adjusted EPS – diluted $0.27 $0.30 Adjusted EBITDA $30.8M $30.0M 19

  20. Slide 20: Q3 Adjusted Net Income

    Q3 Adjusted Net Income $ sucampo

  21. Slide 21: Q3 Adjusted EBITDA

    Q3 Adjusted EBITDA ae $ sucampo

  22. Slide 22: Q3 Revenue

    Q3 Revenue 22 61.3 3.1 2.3 2.2 2.3 1.9 57.9 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 Q3 2016 Amitiza Japan product sales Amitiza US royalty Amitiza US product sales Collaboration revenue Other Q3 2017

  23. Slide 23: Key Balance Sheet Items

    Key Balance Sheet Items 23 Balance Sheet End 9/30/17 Change End 12/31/16 Cash, Cash Equivalents and Restricted Cash $75M ($123.5M) $198.5M Notes Payable $291.9M $1.4M $290.5M Net Debt $216.9M $124.9M $92.0M • Decrease in cash primarily due to Vtesse acquisition and timing associated with working cap

  24. Slide 24: Closing Remarks

    Closing Remarks Peter Greenleaf, Chairman and CEO 24 24

  25. Slide 25: 2017 Areas of Focus

    2017 Areas of Focus 1. Deliver strong financial performance 2. Accelerate priority clinical programs 3. Evaluate and execute on additional opportunities for growth 25

  26. Slide 26: Q&A Session

    Q&A Session 26

  27. Slide 27: Reconciliation of GAAP Net Income to Non-GAAP Net Income

    Reconciliation of GAAP Net Income to Non - GAAP Net Income 27 RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME (in thousands, except per share amounts) Three Months Ended Three Months Ended September 30, 2017 September 30, 2016 Adjusted Net Income: GAAP net income 10,367 8,092 Amortization o

  28. Slide 28: Reconciliation of Income from Operations to Adjusted EBITDA

    Reconciliation of Income from Operations to Adjusted EBITDA 28 RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (in thousands) Three Months Ended Three Months Ended September 30, 2017 September 30, 2016 GAAP net income 10,367 8,092 Adjustments: Income taxes 7,204 7,410 Interest expense 2,956 5,8

Sucampo Pharmaceuticals — Q3 2017 Earnings Presentation on 6ix